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Abstract 
Background: The present research aimed to investigate the efficacy of a multifaceted 
intervention that included motivational interviewing and psychoeducation in improving 
medication adherence among patients with bipolar disorder. 
Method: A multicenter, cluster randomized, observer-blind, controlled, parallel-group trial was 
conducted in ten academic centers in Iran. Patients with BD were randomly assigned to the 
experimental group (EXP; n=136) or the usual care group (UC; n=134). The EXP group received 
five sessions of motivational interviewing and psychoeducation together with their family 
members. The primary outcome measure was changes in scores on the Medication Adherence 
Rating Scale (MARS) from baseline to 6-months post-intervention. Other outcome measures 
included serum levels of mood stabilizers, clinical symptoms, quality of life, as well as measures 
of intention, beliefs about medicine, perceived behavioral control, automaticity, action and 
coping planning, and adverse reactions.  
Results: Medication adherence improved over time in both groups, but patients in the EXP 
group improved more (baseline score: 6.03; score at the sixth month: 9.55) than patients in the 
UC group (baseline score: 6.17; score at the sixth month: 6.67). In addition, patients in the EXP 
group showed greater improvement than patients in the UC group in almost all secondary 
outcomes 6 months following the intervention. 
Conclusions: Multifaceted interventions that include motivational-interviewing and 
psychoeducation can significantly improve medication adherence and clinical and functional 
outcomes in patients with BD. 
Trial Registration Number: The trial was registered with theClinicalTrials.gov database 
(NCT02241863) https://clinicaltrials.gov/ct2/show/NCT02241863 
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Introduction  
Bipolar disorder (BD) causes significant disability in personal and social domains, and 
with a prevalence of 1-2% (Merikangas et al., 2007), it imposes a huge burden on society. 
According to a recent meta-analysis, patients with BD spend more than 40% of their time ill 
(Forte et al., 2015). Despite the fact that it is possible to control the symptoms of BD using 
medication, low levels of adherence is a substantial problem and have been reported in up to 
50% of cases (Geddes and Miklowitz, 2013, Lacro et al., 2002, Lingam and Scott, 2002, Scott 
and Pope, 2002a, b). Patients with BD show a much lower rate of routinely and consciously 
taking prescribed medicines (35%) than patients with, for example, schizophrenia (50-60%). 
Consequently, patients with BD tend to have poorer health outcomes, including lower levels of 
daily functioning, psychological health, and quality of life (QoL) (Dean et al., 2004, IsHak et al., 
2012). Therefore, it is important to develop interventions that can promote medication adherence 
(MA).  
Effective interventions are likely to be those that target modifiable determinants of non-
adherence (Berk et al., 2004), such as beliefs and attitudes (Berk et al., 2004, Lingam and Scott, 
2002, Scott and Pope, 2002a). As a result, a few studies (Bauer et al., 2006a, b, Cakir et al., 
2009, Javadpour et al., 2013) have designed behavioral interventions (e.g., behavioral therapy, 
family reliant treatments, psychosocial education, and interpersonal therapies) in an effort to 
promote MA. For example, Parsons et al. used behavioral therapy to improve MA in HIV-
positive people and found reductions in substance abuse (although no significant change in MA, 
perhaps due to the relatively small sample, (Folco et al., 2012). In another study on BD patients, 
eight sessions of psychoeducation yielded better MA and also QoL among participants in the 
intervention group when followed up 2 years later (Javadpour et al., 2013). Other interventions 
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designed to promote MA have focused on increasing communication and support provided by 
family members to patients, and this strategy is popular for the treatment of mental disorders 
such as schizophrenia (Rollnick et al., 2008).  
However, previous studies that have addressed the challenge of MA in patients with BD 
have been somewhat limited in their methods. To the best of our knowledge, all previous studies 
have only used one type of intervention (namely, psychoeducation) in addition to usual care 
(Rouget and Aubry, 2007). The beneficial effects of psychoeducation for patients with BD have 
been demonstrated on a number of different outcomes, including MA, insight improvement, and 
a reduction in symptoms relief for people with BD (Bilderbeck et al., 2016, Hidalgo-Mazzei et 
al., 2016, Kallestad et al., 2016, Rouget and Aubry, 2007). Similar interventions have also been 
shown to reduce the burden of care, as well as distress among family members (Bermúdez-
Ampudia et al., 2016, Hubbard et al., 2016). Given that patients with BD can differ in their 
responses to the same intervention (Culpepper, 2014), it is possible that a multifaceted 
intervention that targets various reasons for non-adherence might result in even better outcomes.  
A second problem with the evidence-base to date is that many (but not all) previous 
studies (Bauer et al., 2006b, Cakir et al., 2009, Javadpour et al., 2013) have primarily used self-
reported questionnaires to measure MA. However, self-reported outcomes may be biased by 
social desirability effects (e.g., patients with BD may feel obligated to report that they have 
followed the instructions of a health professional) and / or memory problems (e.g., patients with 
BD may not remember whether they have taken their medication). Using objective measures of 
adherence, such as serum levels of mood stabilizers, can reduce the possibility of bias and 
provide a more accurate estimate of the effect of an intervention on MA. 
The Present Research  
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Given the importance of developing interventions to promote MA among people with BD 
and the limitations of the current evidence, the present research sought to develop a multifaceted 
intervention and examine the effects of the intervention on self-report and objective indices of 
MA, as well as secondary outcomes that include potential mediators of treatment effects. The 
intervention was centered around motivational interviewing (MI), a client-centered approach that 
seeks to change attitudes and behavior (Lundahl et al., 2013). Although originally developed for 
reducing alcohol dependence, the use of MI has been rapidly expanded to other health-related 
domains. Indeed, a meta-analysis of 48 studies has shown that MI is an effective way to promote 
changes in behavior across multiple healthcare domains such as diabetes, obesity, smoking, and 
HIV treatment (Lundahl et al., 2013). In recent years, MI has also been used to improve MA in 
conditions that require long-term commitment to treatment such as schizophrenia and acute 
coronary syndrome (Depp et al., 2007). Nevertheless, there is scant evidence on the effect of MI 
in improving MA in patients with BD.  
In addition to MI, we also investigated the idea that interventions might benefit from 
including family members, because family members are likely to support patients with BD in 
taking their medications (Williams and Wright, 2014) especially in the East, where culture 
substantially values the family relationship (Tsai et al., 2015). 
Despite the importance of MA (or lack thereof) in patients with BD, a systematic review 
of studies testing the efficacy of interventions designed to improve MA in BD found only five 
studies whose primary outcome was adherence. A meta-analysis of 18 studies showed an OR of 
2.27(95%CI=1.45±3.56) for improvement in adherence in the intervention group compared to 
control groups (MacDonald et al., 2016).To the best of our knowledge, our study is the most 
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comprehensive study to date of a multifaceted intervention to improve the adherence in patients 
with BD.  
Methods  
Design and study population 
 A multicenter, randomized, observer-blind, controlled, parallel-group trial was conducted 
in ten academic centers in Iran: Tehran (three centers), Qazvin, Ahvaz, Semnan, Zanjan, Tabriz, 
Zahedan, and Mashahd between September 2014 and October 2016. Persian speaking patients 
were eligible if they; 1) met the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV-TR) criteria for bipolar I or II disorder simultaneously confirmed by the administration of 
Structured Clinical Interview (SCID); 2) were 18 years or older; 3) were being treated with a 
mood stabilizer; and 4) were not attending weekly or biweekly psychotherapy. Patients were 
excluded if they; 1) had a DSM-IV-TR diagnosis of drug or alcohol misuse disorders (five 
independent researchers administered a semi-structured interview and a structured interview 
based on DSM-IV-TR criteria for alcohol abuse, alcohol dependence and also substance abuse 
excluding nicotine); 2) showed evidence of severe DSM-IV-TR borderline personality; 3) 
needed to change the type and/or the dose of a mood stabilizer; 4) were pregnant or planned to be 
pregnant in the next year; 5) were unable and/or unwilling to provide a written informed consent; 
6) had any organic cerebral cause for bipolar disorder (e.g., multiple sclerosis or stroke); or 7) 
had an intellectual disability. Figure 1 shows the flow of participants through the trial, including 
the number of patients excluded for the various reasons detailed above. 
 All patients and their family members provided informed consent before participating in 
the study. The protocol was prepared in accordance with the Ottawa Statement, the Helsinki 
Declaration and Good Clinical Practice, and ethical review committees at each of the sites 
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approved the trial. The trial was registered in the clinicaltrials.gov registry 
(https://clinicaltrials.gov/ct2/show/NCT02241863). 
Intervention  
 A multifaceted intervention was developed in an effort to improve MA and clinical 
outcomes. The intervention included two components: a) Psychoeducation for the patients and 
their family members and b) motivational interviewing. Detailed information on the intervention 
is provided in the online supplementary materials. 
MI integrity/fidelity 
 To assess treatment fidelity, all sessions were recorded and transcribed. Two trained 
research assistants reviewed each recording in order to determine the proportion of the 
intervention elements that were covered by the facilitators. The Motivational Interview 
Treatment Integrity (MITI) scale was used to assess the integrity of the MI in the EXP group. 
Two separate aspects of treatment fidelity were taken into account: (i) Global variables (i.e., 
empathy, evocation, collaboration, autonomy/support, and direction) and (ii) behavior counts 
(i.e., giving information, asking open-ended and closed-ended questions, providing simple and 
complex reflections, and making other statements categorized as MI adherent or not). Inter-rater 
reliability was computed using intraclass correlation coefficients (ICCs) in a two-way mixed 
model with absolute agreement. The ICCs were found to be adequate for global measures, 
behavior counts, and summary scores (ICCs ranged from 0.69 to 0.92, as reported in online 
Supplementary Table S1). 
Usual Care  
 Patients in the usual care (UC) group received the usual care that is provided to people 
with severe mental illnesses in Iran, which is mainly based on pharmacological interventions and 
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follow-up visits to address and deal with adjustments to the dosage and / or nature of medications 
and management of side effects. There are no national guidelines for the provision of 
psychosocial services such as occupational rehabilitation, supported employment, social skills 
education and family support. However, during last decade, there has been a growing interest in 
providing these services, such that informal psycho-education about social skills and compliance 
with treatment may be provided on some occasions.  
Outcomes  
 The primary outcome measure was medication adherence (MA) measured using self-
report and objective indices. Secondary outcomes included measures of beliefs and psychosocial 
health. All outcomes were measured three times (at baseline before the intervention, and then 
one and six months after the intervention) using the measures described below. Clinical status 
was assessed using the Clinical Global Impressions-Bipolar-Severity of Illness (CGI-BP-S; 
(Spearing et al., 1997) and the Young Mania Rating Scale (YMRS; (Young et al., 1978) and the 
Montgomery Åsberg Depression Rating Scale (MADRS; (Montgomery and Asberg, 1979) were 
used to assess manic and depressive symptoms, respectively. The clinical measures were 
administrated by five psychiatrists who were blinded to the treatment allocation.  
Medication Adherence Rating Scale (MARS) 
 The MARS was used to measure the primary outcome in the study; namely, MA. Patients 
were asked to rate the extent to which five statements describing non-adherent behaviors, such as 
forgetting to take medicines or missing a dose, apply to them on a 5-point Likert scale (1: Always 
to 5: Never)  e.g., Do you ever forget to take your medication? (O'Carroll et al., 2011). The 
MARS has been shown to be relatively unaffected by social desirability effects (O'Carroll et al., 
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2011), and the Persian translation of the MARS (Pakpour et al., 2014) demonstrates 
unidimensionality and high levels of internal consistency (&URQEDFK¶VĮ . 
Plasma level of mood stabilizer 
 The primary outcome of MA was also assessed using objective indices. Specifically, 
plasma levels of mood stabilizers were obtained from biochemistry laboratories at each center, 
and levels of three mood stabilizers were assayed: Lithium, Carbamazepine, and Sodium 
valproate.  
Beliefs about Medicines Questionnaire - Specific (BMQ-Specific) 
 The BMQ-specific (Horne et al., 1999) was used to assess beliefs about medications 
prescribed for personal use and has been shown to be correlated to adherence (Pakpour et al., 
2015). The measure reflects two domains (necessity and concerns) and each domain is assessed 
using five items that patients are asked to indicate their agreement with on a 5-point Likert scale 
(from 1: strongly disagree to 5: strongly agree). The necessity domain assesses SDWLHQWV¶beliefs 
about the necessity of the medication (e.g., Without my medicines I would be very ill), while the 
concerns domain examines SDWLHQWV¶beliefs about the possible adverse effects of the medication 
(e.g., Having to take medicines worries me). Scores can range between 5 and 25, with higher 
scores indicating stronger beliefs about the necessity of the medication or a higher level of 
concern about taking the medicine, respectively. The Persian version of the BMQ has promising 
psychometric properties and has been used to assess beliefs about medications among an Iranian 
sample with diabetes (Aflakseir, 2012). 
Intention  
 3DWLHQWV¶Lntention to take their medication was measured using a questionnaire adapted 
from Pakpour et al. (Pakpour et al., 2014). Patients were asked to indicate their agreement with 
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five statements (e.g., I intend to take regular medication in the future) on a 5-point Likert scale 
(1: completely disagree to 5: completely agree). Internal consistency of the scale was adequate 
(&URQEDFK¶VĮ 0.91). 
Self-monitoring 
Self-monitoring was measured by three items (e.g., During the last week, I have 
consistently monitored when to take my medications, on a 5-point scale from not at all true (1) to 
exactly true (5) (Pakpour et al., 2015)&URQEDFK
VĮIRUWKHVFDOHZDV 
Self-report Behavioral Automaticity Index (SRBAI) 
 The SRBAI comprises four items from Self-Report Habit Index (Gardner et al., 2012), 
that measure the extent to which relevant behaviors are performed automatically (a key 
component of habit, (Orbell and Verplanken, 2010). Each item starts with the stem Behavior X is 
VRPHWKLQJ«and is followed by (1) I do automatically; (2) I do without having to consciously 
remember; (3) I do without thinking; and (4) I start doing before I realize I am doing it (Gardner 
et al., 2012). All items were rated on a 5-point Likert scale (1: disagree to 5: agree).  
Action and coping planning  
 Action planning was measured using four items: I have made a detailed plan regarding 
when / where / how often / how to take medication. Similarly, coping planning was measured 
using four items: ,KDYHPDGHDGHWDLOHGSODQUHJDUGLQJ« (1) what to do if something interferes; 
(2) what to do if I forget to take my medication; (3) how to motivate myself if I don't feel like 
taking my medication; and (4) how to prevent myself from being distracted. All items measuring 
action planning and coping planning were rated on a 5-point Likert scale (1: completely disagree 
to 5: completely agree) and showed high levels of internal consistency in the present research 
&URQEDFK¶VĮ . 
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Perceived behavioral control (PBC) 
 PBC was measured using four items on a 5-point Likert scale (1: completely disagree to 
5: completely agree) that have proved internally consistent in the present research (&URQEDFK¶VĮ
= 0.94). Sample items include: For me to take regular PHGLFDWLRQLQWKHIXWXUHLV« and It is up 
WRPHWRWDNHUHJXODUPHGLFDWLRQ« 
Young Mania Rating Scale (YMRS) 
 The YMRS contains 11 items each describing a specific mania syndrome. Clinicians 
were asked to rate how severely the patients have experienced each syndrome within the past 2 
days. The items include elevated mood, increased motor and activity-energy, sexual interest, 
sleep, irritability, speech rate and amount, language/thought disorder, thought content, 
disruptive/aggressive behavior, appearance, and insight. All items were rated from 0 (absent) to 4 
(the highest level), and four of the items (irritability, speech, thought content, and 
disruptive/aggressive behavior) were double-weighted (McIntyre et al., 2004, Young et al., 
1978) when computing the overall score. 
Montgomery Åsberg Depression Rating Scale (MADRS) 
 The MADRS contains 10-items designed to measure indicators of depression (e.g., 
reduced appetite). The MADRS is designed to be particularly sensitive to the effects of treatment 
(such as antidepressants) among people with mood disorders. Clinicians were asked to respond 
to each of the items on a 7-point scale and total scores could range from 0 (no symptoms of 
depression) to 60 (highest level of depression (Montgomery and Asberg, 1979). 
Clinical Global Impressions-Bipolar-Severity of Illness (CGI-BP-S) 
 The CGI-BP-S is modified from Clinical Global Impressions Scale for specific use with 
patients with BD. The CGI-BP-S comprised three measures to which clinicians were asked to 
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respond using a 7-point Likert scale. The measures evaluated: (1) The severity of illness 
(Considering your total clinical experience with this particular population, how mentally ill is 
the patient at this time?); (2) change from preceding phase (Compared to the phase immediately 
preceding this trial, how much has the patient changed?); (3) change from worst phase 
(&RPSDUHGWRWKHSDWLHQW¶VZRUVWSKDVHRILOOQHVVSULRUWRWKHFXUUHQWPHGLFDWLRQWULDORUGXULQJ
the early titration phase, how much has the patients changed?). A lower score on the CGI-BP-S 
suggests a better condition (Spearing et al., 1997) 
Quality of Life in Bipolar Disorder scale (QoL.BD) 
 The QoL.BD contains 12 items and is designed to capture SDWLHQWV¶subjective 
perceptions of BD-specific QoL. Each item asks about a specific experience in the past week 
(e.g., Felt physically well). Patients are asked to respond on a 5-point Likert scale (1: strongly 
agree to 5: strongly disagree), and a higher score represents a higher level of QoL (Michalak et 
al., 2010). 
Adverse drug reaction (ADR) 
 Adverse reactions to the prescribed medications were assessed using a questionnaire 
adapted from the clinical monitoring form for mood disorders (Sachs et al., 2002). Patients were 
asked to indicate the severity of nine side effects (e.g., tremor, dry mouth, etc.) on a five-point 
Likert scale, ranging from none (0) to severe (4). A total score was computed as the sum of the 
severity of each side effect and could range from 0 to 36 with higher scores indicating more 
severe side effects.  
Randomization and masking  
 In order to prevent contamination between the EXP and UC groups, centers were used as 
unit of randomization rather than patients. Trained professionals at each center (e.g., physicians 
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and nurses) enrolled participants. Centers were allocated in a 1:1 ratio to either the EXP or UC 
groups by a computer-generated list of random numbers. Five clusters were assigned to the EXP 
group and 5 clusters to the UC group. Figure 1 illustrates the allocation to condition and the flow 
of participants through the trial.  
 Across centers, 538 patients were referred to the trial: 43 declined to be screened for 
eligibility, 217 did not meet screening criteria, and we lost contact with 8. A total of 270 patients 
underwent baseline assessment and 134 were randomized to the UC group and 136 to the EXP 
group. As a result, each center recruited an average of 26 patients. Assessors, psychologists, and 
psychiatrists were blind to the intervention status of the participants. 
Sample Size  
 The required sample size was calculated based on the primary outcome measure (the 
MARS). It was estimated that 132 patients would be needed in each condition to detect an effect 
size of 1 point in the MARS, with 85% power and a significance level of 5%, assuming an 
intracluster correlation coefficient of 0.05, a mean cluster size equal to 27, and that 10% of the 
patients would likely be lost to follow up.  
Statistical Analysis  
Due to the hierarchical nature of the data (i.e., patients were nested within centers), we 
used multilevel linear mixed modeling to investigate the efficacy of the intervention. Three 
levels of analysis ± time, patients, and centers ± were estimated with a restricted iterative 
generalized least square (RIGLS) estimation. Therefore, for each model, three fixed effects were 
entered; an intercept term, Time and condition (the UC group served as the reference group).  
To decompose the interaction between condition and time, we compared the effects of 
condition at each time point (i.e., one and six months after treatment) on each dependent 
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variable. The Benjamini and Hochberg false discovery rate was used to adjust p-values for 
multiple comparisons. In addition, .UXOODQG0DF.LQQRQ¶VWKUHH-step recommendations for 
conducting mediation analyses were performed to identify potential mediators of treatment 
effects (Krull and MacKinnon, 1999). All tests were two sided with a significance level of <0.05 
and analyses were performed on an intent-to-treat basis using MLwiN 2.27 software. 
Results  
Randomization Check 
 Table 1 summarizes the baseline and clinical characteristics of the two groups. About 
51% of the participants in the UC group and 55% of the participants in the EXP group were 
females and the mean age of the patients was 41.2 (6.4) years in the UC group and 41.8 (8.4) in 
the EXP group. The mean age of onset of BD was 24 years for both groups.  
Effects of the Intervention on the Primary Outcome: Medication Adherence 
Table 2 provides the descriptive statistics for all outcome measures by condition and 
time. Tables 3 and 4 show the findings of three-level multiple linear regression models 
examining the effect of the intervention on outcomes. MA improved over time in both the EXP 
and UC groups. However, scores on the MARS indicated a greater improvement in MA among 
patients in the EXP group: Mbaseline= 6.03 (SD = 2.56) and Msix months = 9.55 (SD = 3.88); than 
among patients in the UC group: Mbaseline = 6.17 (SD = 2.90) and Msix months = 6.67 (SD = 2.93). In 
support of this idea, after taking into account the study center and  repeated measurement over 
time, our multilevel mixed models showed that patients in the EXP group had significantly 
higher MARS scores than did patients in the UC group both one (B=3.15; p<0.001) and six 
months (B=3.20; p<0.001) after the intervention (Table 3).  
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Analysis of the objective measures of MA; namely, plasma level of mood stabilizers, 
indicated that patients in the UC group had slightly decreased levels of Lithium (baseline: 0.660 
mmol/L; six month: 0.596 mmol/L), Carbamazepine (baseline: 5.580 mcg/mL; six month: 5.472 
mcg/mL), and Sodium valproate (baseline: 41.255 mcg/mL, six month: 41.001 mcg/mL) at six 
months post-intervention, suggesting that they may not have been adhering to their medication 
regimen. In contrast, patients in the EXP group had increased levels of Lithium (baseline: 0.665 
mmol/L; six month: 0.698 mmol/L), Carbamazepine (baseline: 5.596 mcg/mL; six month: 6.147 
mcg/mL), and Sodium valproate (baseline: 40.094 mcg/mL; six month: 43.048 mcg/mL), 
supporting the beneficial effects of the intervention on MA suggested by the self-report measure 
of adherence. After controlling for study center and repeated measurement, patients in the EXP 
group had significantly higher plasma levels of mood stabilizers than did patients in the UC 
group at one month (B = 0.108 for Lithium, 1.53 for Carbamazepine, and 3.62 for Sodium 
valproate; p < 0.001), and six months (B = 0.178 for Lithium, 1.40 for Carbamazepine, and 5.28 
for Sodium valproate; p < 0.001) post-intervention (see Supplementary Table S2).  
Effects of the Intervention on Secondary Outcomes  
Almost all secondary outcomes improved over time in the EXP group (see Table 2), and 
the findings of multiple linear regression models (reported in Tables 3 and 4) show that patients 
in the EXP group had significantly better outcomes on all secondary measures one month and six 
months after the intervention, compared with patients in the UC group, except for the measure of 
quality of life at one month follow-up. Therefore, patients in the EXP group had stronger 
intentions to take their medication, believe that they had more control over so doing, that taking 
their medication was more automatic, and were more likely to form action and coping plans to 
promote MA.  
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There was also evidence of a decrease in clinical symptoms among patients in the EXP 
group, relative to patients in the UC group, as shown by significant effects of group on the 
YMRS (B=-5.32; p<0.001), CGI-BP-S (B=-0.528; p<0.001), and MARDS (B=-4.54; p<0.001). 
Furthermore, the quality of life of patients in the EXP group improved significantly more than 
among patients in the UC group (B=1.17; p=0.025).  
Mediation Analyses 
Table S3 in the supplementary materials shows the direct and mediated effects of group 
on MA and quality of life (QoL). The effect of the intervention on self-reported MA were 
mediated by changes in beliefs about medication (i.e., beliefs about the necessity of taking the 
medication and concern about the possible adverse effects of the medication), intention, self-
monitoring, action planning, and coping planning. In turn, MA mediated the effect of the 
intervention on QoL.  
We also examined whether self-reported MA (i.e., scores on the MARS) mediated the 
effect of the intervention on plasma levels of mood stabilizers. The results of the mediation 
analysis indicated that self-reported MA mediated the effect of the intervention on improvements 
in plasma levels of mood stabilizers. Specifically, scores on the MARS mediated the effect of the 
intervention effect on improvements in Serum Lithium levels at one month (B= 0.32; SE= 0.10; 
p<0.001) and six month (B= 0.42; SE= 0.07; p<0.001) follow-ups, improvements in Serum 
Carbamazepine levels at one month (B= 2.46; SE= 0.36; p<0.001) and six month (B= 2.59; SE= 
0.49; p<0.001) follow-ups, and on improvements in Serum Sodium Valproate levels at one 
month (B= 2.17; SE= 0.68; p<0.001) and six month (B= 1.92; SE= 0.62; p<0.001) follow-ups. 
Discussion 
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The aim of the present research was to assess the efficacy of a multifaceted intervention 
on MA and health outcomes in patients with BD. We found that a combination of brief sessions 
of MI, together with psychoeducation and efforts to engage family members in promoting 
adherence led to significant improvements in objective and self-report measures of MA, as well 
as in various clinical and functional outcomes compared with usual care. As such, we hope that 
the findings are informative to mental health clinicians seeking to promote MA among patients 
with BD and provide a rationale for designing and implementing multifaceted interventions to 
improve MA in such patients.  
A few prior studies have investigated whether interventions based on MI can improve 
MA in patients with BD. In a quasi-experimental pilot study of 21 elderly subjects with BD, 
Depp et al. showed that a multifaceted intervention including motivational training improved 
MA, as well as depressive symptoms and QoL (Depp et al., 2007). However, this was only a 
preliminary pilot study with a simple training intervention and a limited outcome measure. 
Another study on patients with BD in Iran, showed the effectiveness of an intervention based on 
psychoeducation. This study included an 18 month follow up and measured quality of life, 
medication compliance as well as frequency of hospitalization showing considerable 
improvements in each outcome (Javadpour et al., 2013).However, the study only involved one 
center with 108 patients the intervention only used psychoeducation and did not include family 
members.  
In addition to MI, our intervention included other components, namely psychoeducation 
and engagement of a family member. We found promising effects of the intervention on both 
self-reported and objective measures of MA. Furthermore, our findings also pointed to 
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improvements in symptoms and QoL, which mediation analyses indicated can be attributed to 
improved MA.  
Strengths and limitations 
The present research had several strengths. First, we used both self-report and objective 
outcome measures to ensure the validity of our findings. Second, using multiple outcome 
measures targeting different domains allowed us to look at the effect of the intervention on 
different aspects of health and functioning. Third, we used a multilevel linear mixed model to 
evaluate the effect of intervention on outcomes. 
Our findings should be interpreted in light of some limitations, however. First, family 
engagement constituted an important component of the intervention in the present research. 
While we deem this to be a strength of our multifaceted approach, we acknowledge that family 
likely plays a more significant role in individuals who live in Middle Eastern cultures than in 
other, more Western societies (Daneshpour, 1998). Therefore, the effect of the family component 
of our intervention might not necessarily be generalizable to other cultures. Second, we did not 
assess the effect of our intervention beyond six months of follow-up. However, a meta-analysis 
by MacDonald and colleagues showed that the effects of interventions on MA seemed to be 
durable for up to two years (MacDonald et al., 2016). There is no reason to believe that the 
effects of the present intervention might not also be maintained over this period. Third, it might 
be argued that a longer intervention might improve adherence rates even further. However, the 
feasibility of interventions should be considered in term of time and cost as well as efficacy as 
longer interventions may require greater investment of resources for a relatively small 
improvement in outcomes. Finally, a natural downside to a multifaceted approach to intervention 
is that it is difficult to isolate which part of the intervention was most effective. Future research 
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might usefully adopt factorial designs that systematically manipulate and compare different 
components of the intervention (e.g., the intervention with and without family support) in an 
effort to identify the active ingredients. 
Conclusion 
The present findings provide robust evidence that a multifaceted intervention based on 
MI, psychoeducation, and attempts to engage family members can improve MA among patients 
with BD. The implication is that health care professionals, especially those who deal with mental 
health aspects of people with psychiatric disorders such as BD, may use our findings to improve 
MA and adjust clinical symptoms in their clients. 
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Tables  
Table 1: Baseline and Clinical Characteristics of Patients by Condition  
 
Mean (SD) or n (%) 
 
Usual care (n = 136) Experimental (n = 134) 
Age (year) 41.2 (6.4) 41.8(8.4) 
Age at onset (year) 24.3 (6.1) 24.0 (5.9) 
Sex   
Male 67 (49.3%) 60 (44.8%) 
Female 69 (50.7%) 74 (55.2%) 
Education (year) 6.9 (3.4) 6.2 (4.0) 
Duration of illness (year) 8.2 (5.6) 8.6 (5.3) 
Monthly family income (US$)   
High (>1000$) 26 (19.1%) 15 (11.2%) 
Intermediate (500-1000$) 78 (57.4%) 92 (68.7%) 
Low (<500$) 32 (23.5%) 27 (20.1%) 
Bipolar disorder type    
I 114 (83.8%) 110 (82.1%) 
II 22 (16.2%) 24 (17.9%) 
Living status    
Living with partner  57 (41.9%) 52 (38.8%) 
Single  79 (58.1%) 82 (61.2%) 
Total number of episodes  8.3 (5.7) 8.5 (6.1) 
Number of hospitalizations 2.1 (0.49) 2.2 (0.5) 
Mood stabilizers (Yes)   
Lithium 57 (41.9%) 56 (41.8%) 
Carbamazepine  23 (16.9%) 19 (14.2%) 
Sodium valproate 56 (41.2%) 59 (44.0%) 
Antipsychotics (Yes) 34 (25.0%) 31 (23.1%) 
Mood stabilizer monotherapy (Yes) 58 (42.6%) 54 (40.3%) 
Drug dose at inclusion (mg)    
Lithium 980.6 (212.8) 970.1 (200.1) 
Carbamazepine  640 (173.2) 651 (171.9) 
Sodium valproate 960 (141.9) 958 (134.6) 
The total numbers of taking drugs 2.3 (1.0) 2.1 (1.2) 
Body mass index (kg/m2) 26.8 (4.2) 25.9 (4.0) 
Number of centers 5 5 
Number of patients in each center 26.6 (3.1) 26.1 (3.4) 
Note. SD = standard deviation.
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Table 2: Descriptive Statistics for all Outcome Measures by Condition and Time 
Variable  Group  Mean (SD)/missing n 
  Baseline One month post-
intervention 
Six months post-
intervention 
MARS UC 6.17 (2.90)/0 6.77 (2.85)/4 6.67 (2.93)/7 
EXP 6.03 (2.56)/0 9.53 (3.84)/1 9.55 (3.88)/9 
BMQ necessity UC 14.59 (2.31)/0 14.52 (2.20)/2 14.54 (3.01)/8 
EXP 14.43 (2.29)/1 18.69 (2.49)/2 18.64 (2.48)/10 
BMQ concerns UC 13.19 (3.97)/0 13.22 (3.92)/4 13.20 (4.13)/12 
EXP 12.90 (3.31)/0 6.04 (3.80)/1 5.90 (3.75)/9 
Perceived behavioral control UC 2.58 (0.92)/4 2.61 (0.95)/3 2.56 (0.97)/8 
EXP 2.55 (0.90)/0 2.86 (1.06)/3 2.89 (1.13)/9 
Intention  UC 2.73 (0.65)/0 2.78 (0.69)/3 2.75 (0.71)/10 
EXP 2.79 (0.75)/0 3.45 (1.12)/1 3.43 (1.14)/11 
Self-monitoring  UC 1.99 (0.42)/2 1.96 (0.52)/0 1.94 (0.43)/10 
EXP 2.05 (0.53)/1 2.57 (1.03)/2 2.54 (1.01)/12 
Action planning  UC 1.91 (0.51)/0 1.89 (0.55)/3 1.86 (0.56)/9 
EXP 1.90 (0.54)/1 2.64 (1.17)/4 2.66 (1.34)/9 
Coping planning  UC 1.67 (0.54)/0 1.64 (0.55)/4 1.65 (0.56)/9 
EXP 1.65 (0.59)/1 2.40 (1.28)/5 2.39 (1.39)/9 
SRBAI UC 1.88 (0.82)/0 1.87 (0.83)/2 1.79 (0.88)/8 
EXP 1.90 (0.83)/0 2.14 (0.90)/4 2.20 (0.93)/11 
QoL.BD UC 39.38 (9.18)/0 39.42 (9.26)/3 39.18 (9.27)/9 
EXP 39.14 (11.34)/0 40.90 (11.63)/2 43.56 (12.37)/11 
YMRS UC 15.57 (2.28)/0 15.59 (2.46)/3 15.61 (2.35)/7 
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EXP 15.32 (2.76)/0 12.23 (2.19)/1 10.04 (2.01)/9 
CGI-BP-S UC 4.55 (0.65)/0 4.56 (0.61)/2 4.57 (0.47)/7 
EXP 4.60 (0.75)/0 4.52 (0.51)/2 4.18 (0.43)/9 
MADRS UC 21.82 (5.81)/0 21.37 (4.74)/2 21.28 (4.85)/7 
EXP 22.21 (5.71)/0 17.08 (7.67)/3 17.13 (7.55)/9 
ADR  UC 10.03 (2.97)/3 10.00 (2.99)/6 9.98 (2.79)/9 
EXP 9.94 (2.95)/4 10.09 (2.88)/3 10.15 (2.89)/12 
Serum Lithium level 
(mmol/L) 
UC 0.66 (0.15)/0 0.601 (0.22)/2 0.596 (0.227)/4 
EXP 0.67 (0.18)/0 0.694 (0.23)/1 0.698 (0.241)/2 
Serum Carbamazepine level 
(mcg/mL) 
UC 5.58 (1.40)/0 5.496 (1.39)/2 5.472 (1.461)/1 
EXP 5.60 (1.51)/0 5.948 (1.84)/1 6.147 (1.680)/3 
Serum Sodium valproate 
level (mcg/mL) 
UC 41.26 (16.45)/0 41.09 (16.73)/2 41.001 (17.746)/4 
EXP 40.90 (18.78)/0 42.55 (18.19)/0 43.048 (19.224)/3 
Note. SD = standard deviation. UC = usual care group. EXP = experimental group. BMQ = Beliefs about 
Medicines Questionnaire. SRBAI = Self-report Behavioral Automaticity Index. MARS = Medication 
Adherence Rating Scale. QoL.BD = Quality of Life in Bipolar Disorder scale. YMRS = Young Mania 
Rating Scale. CGI-BP-S = Clinical Global Impressions-Bipolar-Severity of Illness. MADRS = 
Montgomery±Åsberg Depression Rating Scale. ADR = Adverse drug reaction or adverse drug effect. 
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Table 3: Three-level Multiple Linear Regression Models predicting Medication Adherence, Intention, Perceived Behavioral Control, 
Automaticity of Medication Taking, Self-Monitoring, Action and Coping Planning 
Variable  MARS INT PBC SRBAI SM ACP CP 
 Ǻ (SE) p-
value Ǻ (SE) 
p-
value Ǻ (SE) 
p-
value Ǻ (SE) 
p-
value Ǻ (SE) 
p-
value Ǻ(SE) 
p-
value Ǻ(SE) 
p-
value 
Group  
(Ref: UC) 
0.69 
(0.61) 0.26 
0.13 
(0.13) 0.39 
0.09 
(0.18) 0.80 
0.009 
(0.15) 0.99 
0.07 
(0.15) 0.57 
0.11 
(0.13) 0.49 
0.07 
(0.12) 0.47 
Time  
(Ref: baseline)                
One month 0.38 
(0.16) 0.018 
0.09 
(0.04) 0.02 
0.06 
(0.04) 0.13 
0.02 
(0.04) 0.62 
0.04 
(0.04) 0.31 
0.03 
(0.04) 0.45 
0.03 
(0.04) 0.45 
Six months 0.25 
(0.16) 0.12 
0.02 
(0.04) 0.56 
0.06 
(0.04) 0.13 
0.07 
(0.04) 0.05 
0.06 
(0.04) 0.16 
0.05 
(0.04) 0.29 
0.04 
(0.04) 0.29 
Group × Time   
            
EXP vs. UC at 
one month 
3.15 
(0.230) <0.001 
0.64 
(0.05) <0.001 
0.59 
(0.06) <0.001 
0.45 
(0.05) <0.001 
0.55 
(0.06) <0.001 
0.76 
(0.06) <0.001 
0.77 
(0.06) <0.001 
EXP vs. UC at 
six months 
3.20 
(0.23) <0.001 
0.60 
(0.05) <0.001 
0.59 
(0.05) <0.001 
0.43 
(0.05) <0.001 
0.50 
(0.06) <0.001 
0.78 
(0.06) <0.001 
0.78 
(0.06) <0.001 
Intercept 10.88 
(2.15) <0.001 
2.88 
(0.38) <0.001 
2.84 
(0.46) <0.001 
2.29 
(0.43) <0.001 
2.54 
(0.32) <0.001 
2.42 
(0.39) <0.001 
2.18 
(0.388) <0.001 ɐොʹ (patients)  1.91 (0.62) 0.003 0.11 (0.03) 0.002 0.20 (0.06) <0.001 0.13 (0.04) 0.002 0.15 (0.04) <0.001 0.08 (0.03) 0.007 0.09 (0.03) 0.003 ߪොݏܿʹ (centers)  15.16 (0.94) <0.001 0.41 (0.03) <0.001 0.61 (0.04) <0.001 0.57 (0.04) <0.001 0.21 (0.02) <0.001 0.42 (0.030) <0.001 0.42 (0.03) <0.001 
Note. UC = usual care group. EXP = experimental group. MARS = Medication Adherence Rating Scale. INT = intention. PBC = Perceived 
behavioral control. SRBAI = Self-report Behavioral Automaticity Index. SM = Self-monitoring. ACP = Action planning. CP = Coping planning. 
ADR = Adverse drug reaction. 
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Table 4: Three-level Multiple Linear Regression Models Predicting Beliefs about Medication, Mania Symptoms, Severity of Illness, 
Depression, and Quality of Life 
Variable  BMQ specific 
necessity 
BMQ specific 
concerns 
YMRS CGI-BP-S MARDS QoL.BD ADR 
 
Ǻ 
(SE) 
p-
value 
Ǻ 
(SE) 
p-
value 
Ǻ 
(SE) 
p-
value 
Ǻ(SE) p-
value 
Ǻ
(SE) 
p-
value 
Ǻ
(SE) 
p-
value 
Ǻ
(SE) 
p-
value 
Group  
(Ref: 
UC) 
0.02 
(0.58) 
0.97 -0.20 
(0.78) 
0.80 -0.10 
(0.44) 
0.81 -0.08 
(0.16) 
0.62 -0.48 
(1.26) 
0.71 1.21 
(1.07) 
0.26 0.08 
(0.11) 
0.46 
 
Time  
(Ref: 
baseline)  
              
One 
month 
0.07 
(0.12) 
0.59 -0.18 
(0.19) 
0.35 -0.02 
(0.18) 
0.91 0.01 
(0.03) 
0.81 -0.45 
(0.23) 
0.055 0.27 
(0.37) 
0.46 0.10 
(0.07) 
0.15 
Six 
months 
0.54 
(0.12) 
<0.001 -0.24 
(0.19) 
0.21 -0.04 
(0.01) 
<0.001 0.03 
(0.03) 
0.33 -0.60 
(0.24) 
0.012 0.031 
(0.37) 
0.93 0.16 
(0.14) 
0.25 
Group × 
Time 
              
EXP vs. 
UC at 
one 
month 
4.51 
(0.17) 
<0.001 -6.67 
(0.27) 
<0.001 -3.1 
(0.01) 
<0.001 -0.26 
(0.05) 
<0.001 -4.70 
(0.33) 
<0.001 0.93 
(0.55) 
0.09 0.14 
(0.09) 
0.12 
EXP vs. 
UC at six 
months 
4.83 
(0.17) 
<0.001 -6.82 
(0.28) 
<0.001 -5.39 
(0.01) 
<0.001 -0.53 
(0.05) 
<0.001 -4.54 
(0.33) 
<0.001 1.40 
(0.52) 
0.025 0.20 
(0.12) 
0.09 
Intercept 15.39 
(1.31) 
<0.001 10.47 
(1.72) 
<0.001 13.41 
(1.34) 
<0.001 5.00 
(0.373) 
<0.001 24.09 
(2.69) 
<0.001 44.99 
(4.54) 
<0.001 6.68 
(0.33) 
<0.001 ોොܛܜ૛  
(patients)  
2.25 
(0.62) 
<0.001 4.12 
(1.12) 
<0.001 1.20 
(0.36) 
0.002 0.165 
(0.048) 
<0.001 10.88 
(2.99) 
<0.001 3.92 
(1.92) 
0.051 0.512 
(0.13) 
<0.001 
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࣌ො࢙ࢉ૛  
(centers)  
4.63 
(0.31) 
<0.001 7.18 
(0.52) 
<0.001 6.35 
(0.36) 
<0.001 0.384 
(0.025) 
<0.001 19.36 
(1.27) 
<0.001 71.19 
(4.45) 
<0.001 0.42 
(0.11) 
<0.001 
Note. UC = usual care group. EXP = experimental group. BMQ = Beliefs about Medicines Questionnaire. YMRS = Young Mania Rating Scale. 
CGI-BP-S = Clinical Global Impressions-Bipolar-Severity of Illness. MARDS = Montgomery Åsberg Depression Rating Scale. QoL.BD = 
Quality of Life in Bipolar Disorder scale. ADR = Adverse drug reaction. 
 
 Figure 1: Flow of Participants through the Trial 
Assessed for eligibility (n= 538) 
Excluded (n= 268) 
Did not meet the inclusion criteria (n=217):  
¾ drug or alcohol misuse disorders (n=182) 
¾ pregnant (n=3) 
¾ severe borderline personality (n=32)  
Declined to participate (n= 43) 
Lost contact (n= 8) 
 
Analyzed (n=136) 
Excluded from analysis (n=0) 
Lost to follow-up (n= 7) 
Lost contact (n=4) 
Moved away (n=2) 
Refused (n=1) 
 
Allocated to usual care (n=136) 
Received allocated intervention (n= 136) 
Did not receive allocated intervention (n= 0) 
Lost to follow-up (n= 9) 
Lost contact (n=6) 
Moved away (n=3) 
Refused (n = 0) 
Allocated to intervention (n= 134) 
Received allocated intervention (n= 134) 
Did not receive allocated intervention (n= 0) 
Analyzed (n= 134) 
Excluded from analysis (n=0) 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 270) 
Enrollment 
  
a) Psychoeducation 
At least one family member (i.e., a spouse, partner, parent, or sibling) in the 
experimental (EXP) group was invited to attend two sessions of group psychoeducation 
in the outpatient clinic. Each session was conducted by a board-certified psychiatrist and 
lasted 70 minutes, with a 15-minute break. At the sessions, the family members and the 
patients were given information about the aetiology, symptoms, and prognosis of BD, as 
well as mood stabilizers, antidepressants, and their possible side effects. Each family 
member was also provided with information about the importance of MA and the risks of 
discontinuing the medication. At the end of the sessions, the family members were given 
a booklet providing information about BD and possible drug treatments.  
b) Motivational interviewing (MI) 
The goal of the MI sessions was to reduce resistance and overcome ambivalence 
about taking medication. Patients in the EXP group attended three sessions over 1 month, 
each lasting 40 to 65 minutes. All of the sessions were held in a quiet, private, and 
comfortable setting inside the outpatient clinics. Seven trained and registered health 
psychologists delivered the individual counseling sessions (all of whom had over 5 years 
of experience working in psychiatric settings). The health psychologists were trained in 
MI techniques by an experienced MI trainer (the first author) in two weeks that focused 
on didactic and experimental learning techniques. The goals of these training sessions 
were to convey the spirit, processes, and skills of MI in an effort to help the health 
psychologists to conduct the MI competently. The first week provided an introduction to 
MI and the application of MI to clinical training. The second week focused on advanced 
clinical training, supervisor training, and training for trainers. The content of the sessions 
was selected based on Motivational Interviewing Training New Trainers Manual 
(http://www.motivationalinterview.org).  
  
Once trained, the facilitators used the following MI techniques to help the patients 
to take their medication regularly: Open-ended questions, rolling with resistance, setting 
agenda and eliciting self-motivational statements, change talk and affirmations.  
The first session was designed to prepare the patient for the MI. The facilitator 
introduced themselves to the patients and assured them that the conservations would be 
kept private. Afterward, the facilitator encouraged the patients to discuss and list any 
concerns that may interfere with their willingness and motivation to receive psychiatric 
WUHDWPHQWDQGWDNHPHGLFDWLRQE\DVNLQJVRPHEDVLFTXHVWLRQVVXFKDV³What do you call 
your problem?´³:KDWGR\RXWKLQNKDVFDXVHG\RXUSUREOHP"´DQG³What do you fear 
most about your illness?´)DFLOLWDWRUVDOVRSURYLGHGLQIRUPDWLRQRQWKHPHGLFDWLRQWKDW
patients should take (dose and timing, adverse effects, contradictions, and treatment 
process).  
During the second session, the facilitators tried to persuade the patients to commit 
to change and adhere to the treatment. Open-HQGHGTXHVWLRQVHJ³So how have things 
JRQHWKLVZHHN"´DQG³+RZKDYH\RXEHHQIHHOLQJ"´) were used to assess new stressors 
and changes in the environment that were likely to affect the patients. The facilitators 
DOVRLQTXLUHGDERXWSDWLHQWV¶DGKHUHQFHDQGWKHUHVSRQVHWRWKHPHGLFDWLRQDQGKHOSHG
each patient to weigh up the perceived costs and benefits of taking medication (e.g., 
³:KDWGR\RXVHHDVWKHSRVLWLYHDQGQHJDWLYHFRQVHTXHQFHVRItaking medication"´). 
The patient¶s UHDGLQHVVWRFKDQJHZDVUDWHGRQDVFDOHIURP,¶PQRWZLOOLQJWRFKDQJH
to 10 (I will do anything that I need to change). The importance of taking medicine 
regularly was also raised by the facilitators and was rated by the patients on a scale from 
0 (least important) to 10 (most important). These questions were followed up by open-
ended questions that invited patients WRIXUWKHUHODERUDWHRQWKHLUFKRLFHVHJ³Why did 
you choose a (current number) instead of a (lower number)?´³What would need to 
  
happen to make it a (higher number)?´7KHpatients were also encouraged to think 
about what it would be like to make the change by imagining future situations; (e.g., ³,I
you were successful in taking medicine regularly, how woXOGWKLQJVEHGLIIHUHQW"´ 
)LQDOO\WKHIDFLOLWDWRUVPHDVXUHGDQGGLVFXVVHGSDWLHQWV¶FRQILGHQFHLQWKHLUDELOLW\WR
FKDQJHE\DVNLQJTXHVWLRQVVXFKDV³On a scale from 0 to 10, where 10 is the most 
confident and 0 is the least, what number would you give for how confident you are that 
you could taking medicine regularly?´ 
The third session addressed potential obstacles to MA. The facilitator helped the 
patients to review their progress, and sought to renew and reinforce their motivation. 
Patients were helped to identify obstacles that might prevent them from taking 
medication, to identify strategies to overcome obstacles that arise, and to build self-
efficacy. In addition, patients were invited to set goals and make plans to support desired 
changes. Worksheets were given to the patients that encouraged them to identify things 
that they would need to do to achieve a given goal. The facilitators also encouraged the 
patients to create an action plan by specifying where, when and how they would take 
their medication. Patients were also asked to anticipate situations in which it might be 
difficult to take medication and were encouraged to identify strategies to overcome these 
barriers (coping planning). 
In addition to the MI sessions for the patients, a single MI session was conducted 
for the family members of the patients in the EXP group. The same facilitators contacted 
each family member by telephone and invited them to attend a single session. At the 
beginning of the session, the family members were encouraged to express their feelings 
about medications and their role in supporting their family members to take their 
medication regularly was discussed. Barriers and facilitators to behavior change were 
also explored and the facilitators helped the family members to identify the pros and cons 
  
of helping the patients to take their medication regularly. The family members rated the 
SDWLHQWV¶OHYHORIFRPPLWPHQWDQGOLNHOLKRRGRIVXFFHVVRQD-10 scale. Family members 
were encouraged to imagine the patients in the future with and without change. Finally, 
family members were asked to help their patients to use reminders (such as phone alarm 
or sticky notes) to improve their MA. 
 Table S1. Descriptive statistics for global measures of Motivational Interview Treatment Integrity 
(MITI), behavior counts, summary scores, and interrater reliability 
Measures Mean Ʋ SD Minimum Maximum ICC 
Global measures     
Evocation 3.99 (0.65) 2 5 0.69 
Collaboration 3.31 (0.32) 2 5 0.71 
Autonomy/support 4.02 (0.51) 1 5 0.73 
Direction 3.99 (0.53) 1 5 0.79 
Empathy  4.48 (0.50) 1 5 0.70 
Behavior counts     
Giving Information 0.34 (0.40) 0  0.81 
MI-Adherent 5.47 (2.64) 0 18 0.92 
MI-Non-Adherent 0.88 (0.93) 0 5 0.87 
Closed Questions 12.83 (8.01) 0 32 0.76 
Open Questions 8.19 (4.03) 0 30 0.81 
Simple Reflections 11.61 (6.12) 0 49 0.68 
Complex Reflections 100.00 (5.81) 1 30 0.80 
Summary scores     
Global Spirit Rating 3.99 (0.47) 2.11 4.81 0.79 
Percent Complex 
Reflections 
50.38 (16.88) 10.01 100.00 0.76 
Percent Open 
Questions 
60.73 (15.90) 20.17 100.00 0.81 
Reflection-to- 
Question Ratio 
2.55 (2.13) 0.37 19.46 0.77 
Percent MI Adherent 96.68 (6.25) 50.00 100.00 0.83 
Note. MI = motivational interviewing. MITI = Motivational Interview Treatment Integrity. ICC 
= intraclass correlation coefficient; used for testing inter-rater reliability between two raters. 
 Table S2. Three-level Multiple Linear Regression Models Predicting Serum Levels 
Variable  Serum Lithium 
level 
Serum Carbamazepine 
level 
Serum Sodium Valproate 
level 
 Ǻ (SE) p-
value 
Ǻ (SE) p-value Ǻ (SE) p-value 
Group (Ref: UC) 0.02 
(0.04) 
0.62 0.08 (0.32) 0.80 0.69 (2.14) 0.74 
Time (Ref: 
baseline)  
      
One month 0.04 
(0.01) 
0.002 0.19 (0.11) 0.07 1.94 (0.52) <0.001 
Six months -0.06 
(0.01) 
<0.001 -0.26 (0.11) 0.016 2.70 (0.52) <0.001 
Group × Time       
EXP vs. UC at one 
month 
0.15 
(0.02) 
<0.001 1.61 (0.15) <0.001 3.62 (0.73) <0.001 
EXP vs. UC at six 
months 
0.20 
(0.02) 
<0.001 1.40 (0.16) <0.001 5.28 (0.74) <0.001 
Intercept 0.80 
(0.09) 
<0.001 6.01 (0.73) <0.001 44.54 (8.56) <0.001 
ɐොʹ (patients)  0.04 (0.003) <0.001 0.66 (0.18) <0.001 18.71 (8.13) 0.022 ߪොݏܿʹ (centers)  0.02 (0.002) <0.001 1.06 (0.10) <0.001 256.87 (15.35) <0.001 
Note. UC = usual care group. EXP = experimental group. ADR = Adverse drug reaction. 
 Table S3: Direct and Mediated Effects of Group on Medication Adherence and Quality of Life (QoL) 
Outcome Time 
(Month) 
Mediator Coefficient (SE) 
A. Intervention 
effect on outcome  
B. Intervention 
effect on mediator 
C. Mediator effect on 
outcome 
Mediated effect 
(=B*C) 
Medication 
adherence 
1 
 3.15 (0.23)**    
BMQ necessity  4.33 (0.17)** 0.13 (0.01)** 0 55** (0.04) 
BMQ concerns  -6.67 (0.27)** -0.07 (0.01)** 0.45** (0.08) 
PBC  0.59 (0.06)** 0.13 (0.10) 0.08 (0.06) 
Intention  0.60 (0.05)** 0.432 (0.12)** 0.26 (0.07)** 
Self-monitoring  0.55 (0.06)** 0.77 (0.110)** 0.42 (0.08)** 
Action planning  0.76 (0.06)** 0.54 (0.10)** 0.41 (0.08)** 
Coping planning  0.77 (0.06)** 0.56 (0.08)** 0.43 (0.07)** 
SRBIA  0.45 (0.05)** 0.11 (0.11) 0.05 (0.05) 
6 
 3.20 (0.23)**    
BMQ necessity  4.77 (0.17)** 0.12 (0.01)** 0.57 (0.05)** 
BMQ concerns  -6.75 (0.28)** -0.06 (0.01)** 0.42 (0.07)** 
PBC  0.58 (0.05)** 0.16 (0.10) 0.09 (0.06) 
  
 
 
 
 
 
 
 
 
BMQ= Beliefs about Medicines Questionnaire; PBC= Perceived behavioral control; SRBIA= Self-report Behavioral Automaticity Index; QoL.BD= Quality 
of Life in Bipolar Disorder scale. *p < 0.05, **p < 0.01 
Intention  0.60 (0.05)** 0.478 (0.11)** 0.29 (0.07)** 
Self monitoring  0.50 (0.06)** 0.79 (0.11)** 0.40 (0.07)** 
Action planning  0.78 (0.06)** 0.54 (0.10)** 0.42 (0.08) 
Coping planning  0.78 (0.06)** 0.52 (0.09)** 0.40 (0.08)** 
SRBIA  0.43 (0.05)** 0.142 (0.10) 0.06 (0.04) 
QoL.BD 
1 Medication 
adherence  0.93 (0.55)** 3.15 (0.23)** 0.04 (0.02)** 0.12 (0.07)** 
6 Medication 
adherence 1.17 (0.52)* 3.20 (0.23)** 0.23 (0.02)** 0.72 (0.09)** 
